Article Text

Download PDFPDF
Chronotropic and Inotropic Effects of Ropivacaine, Bupivacaine, and Lidocaine in the Spontaneously Beating and Electrically Paced Isolated, Perfused Rabbit Heart
  1. Mikko Pitkanen, M.D., PH.D.*,
  2. Benjamin G. Covino, PH.D., M.D.,
  3. Hal S. Feldman, D.SC.** and
  4. Arthur G. Richard, PH.D.
  1. From the Department of Anesthesia, Research Laboratories, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  2. *Visiting Research Fellow,Department of Anesthesia. Helsinki University, Finland
  3. **Assistant Professor.
  4. Associate Professor.
  5. Professor and Chairman.
  6. *Visiting Research Fellow, Department of Anesthesia, Helsinki University, Finland.
  7. **Assistant Professor.
  8. Associate Professor.
  9. Professor and Chairman.
  1. Address reprint requests to Hal S. Feldman, D.Sc., BWH Anesthesia Research Laboratories, I Innovation Dr., Worcester, MA 01605.

Abstract

Background and Objectives. The purpose of this study was to compare the inotropic and chronotropic effects of ropivacaine, bupivacaine, and lidocaine in an isolated, spontaneously beating rabbit heart preparation. The ability to electrically pace the heart in the presence of local anesthetic also was examined.

Methods. Hearts were perfused with Krebs-Hense-leit solution, then exposed to ropivacaine or bupivacaine at 1, 6, or 13 μg/ml or lidocaine at 6, 20, or 40 μg/ml ( n = 6, each concentration). Left ventricular pressure, left ventricular dP/dt (rate of change derivation from analog waveform of the left ventricular pressure wave), pulmonary artery flow, oxygen consumption, and electrocardiogram were monitored through-out the studies. Drug exposure was for 30 minutes or until a 75% decrease in left ventricular pressure occurred.

Results. All preparations were exposed to 1 μg/ml bupivacaine or ropivacaine and 6 μg/ml lidocaine for the full 30 minutes. At the intermediate concentrations, only one of six bupivacaine preparations (6 μg/ml) survived the full 30-minute exposure period, compared to six of six preparations for both ropivacaine (6 μg/ml) and lidocaine (20 μg/ml; p < 0.05). Similar results were found with exposure to the highest concentrations of these local anesthetics. No electrocardiogram changes were observed with any of the three lidocaine concentrations or with the lowest ropivacaine and bupivacaine concentration. At the intermediate concentration, atrioventricular conduction changes were seen with bupivacaine in five of six preparations, compared to one of six ropivacaine preparations ( p < 0.05). With the high concentration, ventricular tachycardia occurred in four of six bupivacaine preparations, compared to zero of six with ropivacaine ( p < 0.05). In general, left ventricular systolic pressure, dP/dt, heart rate, and oxygen consumption were reduced during exposure to all concentrations of the three local anesthetics. The most profound effects (>75% reduction) were seen with 13 μg/ml bupivacaine. All local anesthetics caused an increase in the voltage required to pace the hearts via the atria. With 6 μg/ml bupivacaine and 13 μg/ml ropivacaine, 50% of the preparations could not be paced via the atria; and with 13 μg/ml bupivacaine, none of the preparations could be paced via the atria. The depressant effects of 6 μg/ml bupivacaine approximated those seen with 13 μg/ml ropivacaine. The reductions in oxygen consumption and pulmonary artery flow were not significantly different between treatment groups.

Conclusion. The results of this study indicate that bupivacaine is more cardiodepressant and arrhythmogenic than either ropivacaine or lidocaine.

  • Anesthetic
  • local
  • ropivacaine
  • bupivacaine
  • lidocaine
  • cardiac effects
  • heart
  • dysrhythmia
  • local anesthetic effects
  • oxygen consumption.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Presented at the annual meeting of the American Society of Anesthesiologists, Las Vegas, October 19-23, 1990.

    Supported in part by a grant from Astra Pain Control AB, Sodertalje, Sweden.

    The authors acknowledge Thomas Manning and Colette Lavoie, for their expert technical assistance, and Ann Marie Doucette, for her expert handling of the data and data analysis.